Molecular Neuroimaging, Pathophysiological Mechanisms, and Drug Discovery

  • Philip McGuire


This chapter aims to review recent neuroimaging studies that have investigated the relationship between neurochemical dysfunction in psychosis and alterations in regional brain structure and function. It will focus on studies in subjects with an at-risk mental state (ARMS), who have a very high risk of developing psychosis within 1–2 years (Yung et al. 1998). Research in this population provides a powerful means of investigating the mechanisms underlying the onset of psychosis, as the same individuals can be studied before and after the onset of illness. Moreover, as most of the subjects are medication naïve, the results are not confounded by the effects of antipsychotic treatment.


Grey Matter Volume Verbal Fluency Recent Neuroimaging Study Cortical Grey Matter Volume Verbal Learning Task 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O’carroll, C., Allen, P., Seal, M., Fletcher, P., Crippa, J., Mechelli, A., Atakan, Z., McGuire, P. (2009a) Delta-9-tetrahydrocannabinol modulates medial temporal and striatal function in humans: a neural basis for the effects of cannabis on learning & psychosis. Archives of General Psychiatry 66: 442–451Google Scholar
  2. Bhattacharyya, S., Morrison, P., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’carroll, C., Seal, M., Allen, P., Mehta, M., Giampietro, V., Kapur, S., Murray, R., Zuardi, A., Crippa, J., Atakan, Z., McGuire, P. (2009b) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (in press)Google Scholar
  3. Borgwardt, S., McGuire, P., Aston, J., Gschwandtner, U., Pfluger, M., Stieglitz, R., Radue, E.W., Reicher-Rossler, A. (2008) Reductions in frontal temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research 106: 108–114CrossRefPubMedGoogle Scholar
  4. Broome, M.R., Woolley, J.B., Johns, L.C., Valmaggia, L.R., Tabraham, P., Gafoor, R., Bramon, E., McGuire, P.K. (2005) Outreach and support in south London (OASIS): Implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry 20: 5–6, 372–378CrossRefGoogle Scholar
  5. Deutsch, S.I., Rosse, R.B., Schwartz, B.L., Mastropaolo, J. (2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clinical Neuropharmacology 24: 43–49CrossRefPubMedGoogle Scholar
  6. Fusar-Poli, P., Howes, O., Allen, P., Broome, M., Valli, I., Montgomery, A., Grasby, P., McGuire, P. (2008) Dopaminergicmodulation of prefrontal functioning in subjects at clinical risk for psychosis: a combined pet–fmri study. Schizophrenia Research 102: 30CrossRefGoogle Scholar
  7. Fusar-Poli, P., Crippa, J., Bhattacharyya, S., Borgwardt, S., Allen, P, Martin-Santos, R., Seal, M., Surguladze, S., O’carroll, C., Atakan, Z., McGuire, P. (2009a) Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry 66: 95–105Google Scholar
  8. Fusar-Poli, P., Howes, O., Allen, P., Broome, M., Valli, I., Montgomery, A., Grasby, P., McGuire, P. (2009b) Altered prefrontal structure and function predicts elevated striatal dopamine function in subjects at high risk of psychosis. Altered prefrontal activation directly related to striatal dopamine dysfunction in people with prodromal symptoms of schizophrenia. Molecular Psychiatry (In Press)Google Scholar
  9. Goff, D.C., Coyle, J.T. (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158: 1367–1377CrossRefPubMedGoogle Scholar
  10. Howes, O., Montgomery, A., Asselin, M.C., Murray, R.M., Grasby, P., McGuire, P. (2007) Molecular imaging studies of the striatal dopamineric system and prediction in the prodromal phase of psychosis. British Journal of Psychiatry 191: 13–18CrossRefGoogle Scholar
  11. Howes, O., Montgomery, A., Asselin, M.C., Murray, R., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., Grasby, P., McGuire, P. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 66: 13–20CrossRefPubMedGoogle Scholar
  12. McGlashan, T., Zipursky, R.B., Perkins, D., Addington, J., Miller, T., Woods, S.W., Hawkins K.A., Hoffman, R.E., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M., Breier, A. (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American J Psychiatry 163: 790–799Google Scholar
  13. McGorry, P.D. Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., et al. (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59: 921–928CrossRefPubMedGoogle Scholar
  14. McGuire, P.K., Bates, J., Goldman-Rakic, P.S. (1991) Interhemispheric integration II: Symmetry and convergence of the corticostriatal connections of the left and right principal sulcus (PS) and the left and right supplementary motor area (SMA) in the rhesus monkey. Cerebral Cortex 1: 408–417CrossRefPubMedGoogle Scholar
  15. McGuire, P.K., Jones, P., Bebbington, P., Toone, B.K., Lewis, S.W., Murray, R.M. (1994) Cannabis and acute psychosis. Schizophrenia Research 13: 161–168CrossRefPubMedGoogle Scholar
  16. McGuire, P., Howes, O., Stone, J., Fusar-Poli, P. (2008) Functional neuroimaging as a tool for drug development in schizophrenia. Trends in Pharmacological Sciences 29: 91–98CrossRefPubMedGoogle Scholar
  17. Moore, T.H., Zammit, S., Lingford-Hughes, A., et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet Jul 28; 370 (9584): 319–328CrossRefGoogle Scholar
  18. Olney, J.W., Farber, N.B. (1995) Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52: 998–1007PubMedGoogle Scholar
  19. Pantelis, C., Velakoulis, D., McGorry, P., Wood, S., Suckling, J., Phillips, L., Yung, A., Bullmore, E., Brewer, W., Soulsby, B., Desmond, P., McGuire, P.K. (2003) Neuroanatomical abnormalities in people who develop psychosis. Lancet 361: 281–288CrossRefPubMedGoogle Scholar
  20. Patil, S.T., Zhang, L., Marteny, F., Lowe, S., Jackson, K., Andreev, B., Avedisova, A., Bardenstein, L., Gurovich, I., Morozova, M., Mosolov, S., Neznanov, N., Reznik, A., Smulevich, A., Tochilov, V., Johnson, B., Monn, J., Schoepp, D. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomised Phase 2 clinical trial. Nature Medicine 13: 1102–1107CrossRefPubMedGoogle Scholar
  21. Pilowsky, L.S., Bressan, R.A., Stone, J.M., Erlandsson, K., Mulligan, R.S., Krystal, J.H., et al. (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Molecular Psychiatry 11: 118–119CrossRefPubMedGoogle Scholar
  22. Ranganathan, M., D’Souza, D.C. (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188(4): 425–444CrossRefGoogle Scholar
  23. Robson, P. (2001) Therapeutic aspects of cannabis and cannabinoids. British Journal of Psychiatry 178: 107–115CrossRefPubMedGoogle Scholar
  24. Ruhrmann, S., Bechdolf, A., Kühn, K., Wagner, M., Schultze-Lutter, F., Janssen, B., Maurer, K., Häfner, H., Gaebel, W., Möller, H., Maier, W., Klosterkötter, J. (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry 191: s88–s95CrossRefGoogle Scholar
  25. Solowij, N., Stephens, R.S., Roffman, R.A., et al. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287(9): 1123–1131, Mar 6, 2002CrossRefPubMedGoogle Scholar
  26. Stone, J., Day, F., Tsagaraki, H., Valli, I., McLean, M., Lythgoe, D., O’Gorman, M., Barker, G., McGuire, P. (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biological Psychiatry 66: 533–539Google Scholar
  27. Theberge, J., Bartha, R., Drost, D.J., Menon, R.S., Malla, A., Takhar, J., et al. (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. American Journal of Psychiatry 159: 1944–1946CrossRefPubMedGoogle Scholar
  28. Theberge, J., Al-Semaan, Y., Williamson, P.C., Menon, R.S., Neufeld, R.W., Rajakumar, N., et al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. American Journal of Psychiatry 160: 2231–2233CrossRefPubMedGoogle Scholar
  29. Williams, G.V., Castner, S.A. (2006) Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 139(1): 263–276CrossRefPubMedGoogle Scholar
  30. Woods, S.W., Tully, E.M., Walsh, B.C., Hawkins, K.A., Callahan, J.L., Cohen, S.J., Mathalon, D.H., Miller, T.H., McGlashan, T.H. (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. British Journal of Psychiatry 191: s96–s101CrossRefGoogle Scholar
  31. Yung, A.R., Phillips, L.J., McGorry, P.D., McFarlane, C.A., Francey, S., Harrigan, S., Patton, G.C., Jackson, H.J. (1998) Prediction of psychosis – a step towards indicated prevention in schizophrenia. British Journal of Psychiatry 172: 14–20Google Scholar
  32. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, A., Guimaraes, F.S. (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research 39(4): 421–429CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Section of NeuroimagingInstitute of PsychiatryLondonUK

Personalised recommendations